Introduction

Thrombotic diseases are a group of conditions characterized by abnormal blood clotting. Several therapies are available for the management of thrombotic disease. This article focuses on sequential therapy with ancrod followed by streptokinase.

What is Sequential Therapy with Ancrod and Streptokinase?

Sequential therapy is a treatment strategy where two or more therapies are used in sequence rather than in combination. Ancrod is a medication that reduces plasma fibrinogen levels, a protein that plays a key role in blood coagulation. Streptokinase is a thrombolytic agent that helps dissolve blood clots by breaking down fibrin, the protein that forms the cross-linking in a blood clot.

How Does Sequential Therapy with Ancrod and Streptokinase Work?

Intravenous infusion of ancrod leads to a significant reduction in plasma fibrinogen, resulting in a highly significant reduction in both plasma and whole blood viscosity. This change in blood properties aids in the dissolution of blood clots. Sequential administration of streptokinase results in a gradual rise in fibrinogen and a slight but significant rise in whole blood and plasma viscosity. This effect contributes to stabilizing the clot and preventing re-occlusion. Together, these medications help to dissolve the existing thrombus and prevent the formation of new clots by inhibiting blood coagulation.

Research Findings

A study was conducted on a series of thrombotic disease patients to assess the effectiveness and safety of sequential therapy with ancrod and streptokinase. The study found that all patients showed clinical improvement, and no hemorrhagic complications resulted.

Conclusion

Sequential therapy with ancrod followed by streptokinase is a promising treatment option for thrombotic disease patients. This therapy helps dissolve clots and prevent re-occlusion, resulting in clinical improvement. Further research is needed to establish the efficacy and safety of this therapy in larger patient populations.

Related Keywords:

• Sequential therapy with ancrod and streptokinase
• Thrombotic disease
• Blood coagulation
• Fibrinogen
• Plasma viscosity
• Intravenous infusion
• Thrombolytic agent
• Fibrin
• Blood clot
• Research findings
• CLot dissolution
• Clinical improvement